Today: 1 May 2026
Browse Category

NYSE:JNJ 24 December 2025 - 3 January 2026

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson stock holds near $207 as New Year’s Day shuts U.S. markets — what to watch next

Johnson & Johnson shares closed up 0.02% at $206.95 on Wednesday, ahead of the New Year’s Day market holiday. The company completed its $3.05 billion acquisition of Halda Therapeutics and plans to appeal a $1.5 billion talc verdict. Drugmakers are set to raise list prices on at least 350 medicines in 2026, Reuters reported. J&J’s fourth-quarter earnings call is set for Jan. 21.
1 January 2026
·
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.
1 January 2026
··
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, adding the RIPTAC oncology platform and lead prostate cancer program. Shares slipped 0.3% to $206.91 in after-hours trading. The company expects about $0.20 dilution to adjusted EPS, split between 2025 and 2026, and will discuss 2026 guidance on its Jan. 21 earnings call.
31 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson has halted a Phase 2b trial of its experimental eczema drug JNJ-5939 after interim results failed to meet efficacy targets, though the therapy was well tolerated. The stock last traded near $207.63, slightly down before the market closed for the weekend. The New York Stock Exchange will reopen Monday.
28 December 2025
··
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson shares closed at $207.63 Friday, down 0.07%, after the company halted a mid-stage trial of its eczema drug JNJ-5939 due to lack of efficacy. The drug was well-tolerated but failed to meet targets in interim analysis. JNJ’s market cap stands near $500 billion, with a 2.5% dividend yield. The stock traded at $207.86 after hours ahead of Monday’s market open.
27 December 2025
··
Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

U.S. stock markets were closed Saturday after Wall Street ended Friday nearly flat; the Dow slipped 0.04%, S&P 500 fell 0.03%, and Nasdaq lost 0.09%. Large-cap healthcare stocks held steady, while biotech lagged. Johnson & Johnson halted a Phase 2 eczema drug trial after missing efficacy goals. Healthcare ETFs closed Friday with XLV at $156.05, XBI at $124.98, and IBB at $171.44.
27 December 2025
Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen Friday, Dec. 26, after the Christmas holiday. Johnson & Johnson shares last traded near $207.78, up 0.6% from the previous close, with recent sessions marked by low volume. The company faces renewed legal pressure after a Baltimore jury ordered it to pay over $1.5 billion in a talc case, with J&J planning to appeal. Over 67,000 talc-related lawsuits remain unresolved.
26 December 2025
·
Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson shares last closed at $207.78 on Dec. 24, up 0.97%, with after-hours trading nearly flat at $207.75 ahead of the Christmas market closure. The New York Stock Exchange was shut Dec. 25 and will reopen Dec. 26. J&J faces ongoing headline risk from talc litigation, including a recent $1.5 billion jury verdict in Baltimore. The company is appealing and disputes the claims.
25 December 2025
·
Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson shares closed up 0.95% at $207.78 in a shortened Christmas Eve session, with trading volume at 2.38 million shares. The move comes as a Baltimore jury ordered J&J to pay over $1.5 billion in a talc cancer case, which the company plans to appeal. U.S. markets closed early and will remain shut for Christmas Day.
24 December 2025
··
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson traded near $207 per share in thin holiday trading Wednesday, keeping its market value around $500 billion. A Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest such verdict to date. J&J said it will appeal. U.S. markets close early at 1 p.m. ET for Christmas Eve.
24 December 2025
···
1 … 3 4 5 6 7 8

Stock Market Today

  • Microsoft Stock Falls 4.6% Despite Strong Q3 Earnings and AI Revenue Surge
    May 1, 2026, 12:24 AM EDT. Microsoft's stock dropped 4.6% despite reporting better-than-expected Q3 fiscal 2026 results, with earnings of $4.27 per share and sales of $82.9 billion, beating forecasts. The company saw 18% sales growth and a 123% surge in artificial intelligence (AI) revenue to $37 billion, making up nearly half its total revenue. However, massive capital investments of $30.9 billion reduced free cash flow by 22% year-on-year to $15.8 billion for the quarter. With a projected free cash flow valuation multiple around 50 times, some analysts caution about the stock's high price relative to growth. Despite strong growth, investors should weigh the risks and consider analyst recommendations before buying Microsoft shares.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:28 AM EDT Microsoft Stock Falls 4.6% Despite Strong Q3 Earnings and AI Revenue Surge May 1, 2026, 12:24 AM EDT. Microsoft's stock dropped 4.6% despite reporting better-than-expected Q3 fiscal 2026 results, with earnings of $4.27 per share and sales of $82.9 billion, beating forecasts. The company saw 18% sales growth and a 123% surge in artificial intelligence (AI) revenue to $37 billion, making up nearly half its total revenue. However, massive capital investments of $30.9 billion reduced free cash flow by 22% year-on-year to $15.8 billion for
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Go toTop